Key Takeaways SLN completed SANRECO enrollment ahead of schedule, accelerating the top-line data to August 2026.SLN is seeking a strategic partner to advance phase III-ready zerlasiran after positive FDA and EMA feedback.Silence Therapeutics regained global rights to SLN312 after AstraZeneca ended the program's development. Shares of Silence Therapeutics (SLN - Free Report) have surged 107% over the past six months, driven by investor optimism around the company's advancing RNA interference (siRNA) pipeline, upcoming clinical data readouts and the long-term growth potential of its lead candidate, divesiran.
Divesiran: SLN’s Major Growth DriverInvestor sentiment has been fueled by the rapid clinical progress of divesiran, Silence Therapeutics’ first-in-class siRNA therapy targeting TMPRSS6 for the treatment of patients with polycythemia vera (PV), a rare myeloproliferative blood cancer characterized by excessive production of red blood cells and elevated hematocrit levels.
The ongoing phase II SANRECO study is evaluating divesiran at a 6 mg dose with every-six-week (Q6W) and every-12-week (Q12W) dosing schedules in patients with PV. The study completed patient enrollment ahead of schedule. As a result, the company accelerated the anticipated top-line data readout from the second half of 2026 to the third quarter of 2026 (August 2026). Positive study data could serve as a significant catalyst for the stock. Earlier phase I data demonstrated meaningful reductions in phlebotomy requirements, improvements in disease-related symptoms and quality of life and a favorable safety profile.
Year to date, shares of Silence Therapeutics have jumped 71.9% against the industry’s 1.5% drop.
Image Source: Zacks Investment Research
SLN’s Other Pipeline Assets on the MoveBeyond divesiran, Silence Therapeutics continues to strengthen its long-term growth outlook through a diversified RNAi pipeline. Zerlasiran (SLN360) is SLNs’ phase III-ready siRNA candidate for cardiovascular disease associated with elevated lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart attack and stroke. In phase I and phase II studies, zerlasiran demonstrated substantial and durable reductions in Lp(a) with infrequent dosing and a favorable safety profile. Following positive regulatory feedback from the FDA and EMA, and the completion of key phase III readiness activities, the company is seeking a strategic partner to advance late-stage development and commercialization of the program.
SLN312 Faces Development Setback Following AstraZeneca ExitAnother promising asset, SLN312, is an siRNA therapy targeting ANGPTL3 for the treatment of dyslipidemia. However, the candidate faced a setback in March, after its former partner, AstraZeneca (AZN - Free Report) , decided to discontinue further development of the program following a phase I study. Although the study demonstrated durable, dose-dependent reductions in ANGPTL3, triglycerides and atherogenic lipoproteins, along with a favorable safety profile and the potential for infrequent dosing, AZN chose not to advance the candidate into later-stage development. As a result, Silence Therapeutics will regain global rights to SLN312 and must now determine the program's future, either by funding its development internally or securing a new strategic partner.
SLN’s Zacks Rank & Stocks to ConsiderSilence Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.48. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 21.3% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have surged 125.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require confirmation in the pivotal Phase 2 readout (August 2026).
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive outlook for its lead drug candidate.
Cantor Fitzgerald initiated coverage of Silence Therapeutics with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially transformative catalyst and supporting a valuation upside of more than 160%.
Ongoing Phase 2 Study Could Be Major CatalystPV is a rare, slow-growing blood cancer that causes the bone marrow to produce too many red blood cells.
SANRECO Phase 2 study evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing, with topline results on track for August 2026.
Cantor analyst Prakhar Agrawal wrote, “We are positive on the upcoming P2 PV trial and expect divesiran to show rusfertide-like efficacy while offering a meaningful dosing convenience advantage (every 6-weeks or every 12 weeks), compared with rusfertide’s weekly dosing regimen.”
Dosing Convenience Seen As Competitive AdvantageThe study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and Fast Track designations.
Cantor noted that KOL checks suggest that, assuming comparable efficacy and safety to rusfertide, even an every 6-week dosing schedule could support meaningful uptake of divesiran in PV.
At a market cap of just $300 million, analyst Agrawal sees Silence Therapeutics as materially undervalued and initiated with an Overweight rating.
The analyst sees a high 75% probabilty of success for the Phase 2 PV trial, supported by divesiran’s strong Phase 1 data in PV with 100% response rate in well-controlled PV patients, and the valuation benchmark set by rusfertide in PV following its positive Phase 2 results.
Cantor says the valuation range implies over 160% upside from current levels. Risk/reward is very attractive for Phase 2.
Silence Therapeutics Price ActionSLN Price Action: Silence Therapeutics shares were up 22.90% at $8.93 at the time of publication on Wednesday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life
Follow-up data show substantial reductions in phlebotomy use persisting after final dose
Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress.
Divesiran data presented at EHA show improvements in PV-related symptoms and quality-of-life, complementing the substantial reductions in phlebotomy use as previously reported. Additional analyses also showed substantial reductions in phlebotomy use persisted well beyond the final dose.
“Data presented at EHA continue to reinforce divesiran’s potential to transform the treatment paradigm for patients with polycythemia vera,” said Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics. “In Phase 1, we observed sustained hematocrit control, symptom improvement, and robust and durable reductions in phlebotomy burden, which persisted after the final dose. These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026.”
Key EHA 2026 Data Highlights
In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies. During the active treatment period, only 5 phlebotomies were required, all occurring in patients classified as “uncontrolled” at baseline with HCT levels greater than 45%. During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported, supporting the prolonged duration of divesiran’s effect. Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. The majority of patients experienced improvements in MPN-10 total symptom scores from baseline through Week 34, indicating potential improvements in disease-related symptoms and overall quality of life. Divesiran was well tolerated, with no dose-limiting toxicities observed. The most common treatment-emergent adverse events (TEAEs) were mild and transient injection-site reactions. No treatment-related serious adverse events or TEAEs leading to discontinuation were reported. The 2026 EHA poster presentation is linked here.
The ongoing Phase 2 SANRECO study (NCT05499013) is evaluating divesiran using Q6W and Q12W dosing regimens in patients with PV. Topline data are expected in August 2026.
SANRECO Phase 1 Study Design
The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously (s.c.) Q6W for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients - defined as those with HCT levels ≤ 45% – as well as those with HCT levels > 45% at baseline on current standard-of-care treatment were enrolled.
SANRECO Phase 2 Study Design
The Phase 2 portion of SANRECO is an ongoing, three-part, global, randomized, placebo-controlled, double-blind study evaluating divesiran in 48 phlebotomy-dependent PV patients. The trial is evaluating the safety and efficacy of divesiran 6 mg administered s.c. Q6W or Q12W in patients with uncontrolled HCT who are phlebotomy-dependent despite standard-of-care treatment which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study is the proportion of patients achieving a response during weeks 18-36, which is defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study are required to have HCT ≥ 45%. Following the placebo-controlled portion of the trial, patients enter the 3-year, double-blind and open label extension periods.
About PV
PV is a rare, myeloproliferative neoplasm – a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit levels. Elevated hematocrit above 45-percent is associated with a four-times higher rate of death from cardiovascular and thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritus and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain hematocrit less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care includes repeated phlebotomies to reduce hematocrit and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and hematocrit.
About Divesiran
Divesiran is Silence’s wholly owned siRNA product candidate developed from its proprietary mRNAi GOLD™ platform that “silences” TMPRSS6 expressed almost exclusively in the liver. TMPRSS6 is a negative regulator of hepcidin, the body's master regulator of iron metabolism including its absorption, distribution, and storage. By silencing TMPRSS6 in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. Divesiran is currently in Phase 2 development for PV and has FDA Fast Track and Orphan Drug designations for PV.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: continued clinical development of divesiran including the proposed SANRECO Phase 2 clinical activities and timelines; the potential therapeutic benefits of the Company’s product candidates; and the anticipated timing of topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress.
Divesiran data presented at EHA show improvements in PV-related symptoms and quality-of-life, complementing the substantial reductions in phlebotomy use as previously reported. Additional analyses also showed substantial reductions in phlebotomy use persisted well beyond the final dose.
“Data presented at EHA continue to reinforce divesiran’s potential to transform the treatment paradigm for patients with polycythemia vera,” said Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics. “In Phase 1, we observed sustained hematocrit control, symptom improvement, and robust and durable reductions in phlebotomy burden, which persisted after the final dose. These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026.”
Key EHA 2026 Data Highlights
In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies. During the active treatment period, only 5 phlebotomies were required, all occurring in patients classified as “uncontrolled” at baseline with HCT levels greater than 45%. During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported, supporting the prolonged duration of divesiran’s effect. Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. The majority of patients experienced improvements in MPN-10 total symptom scores from baseline through Week 34, indicating potential improvements in disease-related symptoms and overall quality of life. Divesiran was well tolerated, with no dose-limiting toxicities observed. The most common treatment-emergent adverse events (TEAEs) were mild and transient injection-site reactions. No treatment-related serious adverse events or TEAEs leading to discontinuation were reported. The 2026 EHA poster presentation is linked here.
The ongoing Phase 2 SANRECO study (NCT05499013) is evaluating divesiran using Q6W and Q12W dosing regimens in patients with PV. Topline data are expected in August 2026.
SANRECO Phase 1 Study Design
The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously (s.c.) Q6W for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients - defined as those with HCT levels ≤ 45% – as well as those with HCT levels > 45% at baseline on current standard-of-care treatment were enrolled.
SANRECO Phase 2 Study Design
The Phase 2 portion of SANRECO is an ongoing, three-part, global, randomized, placebo-controlled, double-blind study evaluating divesiran in 48 phlebotomy-dependent PV patients. The trial is evaluating the safety and efficacy of divesiran 6 mg administered s.c. Q6W or Q12W in patients with uncontrolled HCT who are phlebotomy-dependent despite standard-of-care treatment which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study is the proportion of patients achieving a response during weeks 18-36, which is defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study are required to have HCT ≥ 45%. Following the placebo-controlled portion of the trial, patients enter the 3-year, double-blind and open label extension periods.
About PV
PV is a rare, myeloproliferative neoplasm – a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit levels. Elevated hematocrit above 45-percent is associated with a four-times higher rate of death from cardiovascular and thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritus and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain hematocrit less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care includes repeated phlebotomies to reduce hematocrit and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and hematocrit.
About Divesiran
Divesiran is Silence’s wholly owned siRNA product candidate developed from its proprietary mRNAi GOLD™ platform that “silences” TMPRSS6 expressed almost exclusively in the liver. TMPRSS6 is a negative regulator of hepcidin, the body's master regulator of iron metabolism including its absorption, distribution, and storage. By silencing TMPRSS6 in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. Divesiran is currently in Phase 2 development for PV and has FDA Fast Track and Orphan Drug designations for PV.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: continued clinical development of divesiran including the proposed SANRECO Phase 2 clinical activities and timelines; the potential therapeutic benefits of the Company’s product candidates; and the anticipated timing of topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260611005104/en/
SLN Stock Catalyst: SANRECO Phase 1 Follow-Up DataRecent analyses from the Phase 1 SANRECO study show potential improvements in symptoms and quality of life for patients with polycythemia vera (PV).
Additional analyses also showed reductions in phlebotomy use persisted well beyond the final dose.
The ongoing Phase 2 SANRECO study is on track to deliver topline results in August 2026, further supporting the stock’s upward movement.
William Blair Highlights Divesiran’s Competitive PositionWilliam Blair said Thursday that additional analyses from the Phase 1 SANRECO trial reinforce positive momentum for Silence Therapeutics and divesiran in polycythemia vera (PV), with topline Phase 2 data expected in the third quarter.
Analyst Myles Minter believes divesiran offers comparable efficacy and remains best-in-class among TMPRSS6 silencers. He highlighted its favorable dosing schedule (every 6–12 weeks versus weekly rusfertide injections) and safety profile.
Cardiovascular Pipeline Offers Additional UpsideThe analyst also pointed to Silence's cardiovascular disease pipeline, which targets well-validated pathways, as providing multiple value-creation opportunities for the company's mRNAi GOLD platform.
William Blair reiterated its Outperform rating.
SLN Stock Price Activity: Silence Therapeutics shares were up 2.84% at $6.87 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock/ Yomal2233
Market News and Data brought to you by Benzinga APIs
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Insider and Institutional Ownership 87.1% of Avalo
Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $34.50.
Several research analysts have issued reports on SLN shares. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 13th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Jefferies Financial Group raised Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd.
Read Our Latest Stock Report on Silence Therapeutics
Silence Therapeutics Stock Performance Shares of NASDAQ SLN opened at $5.94 on Friday. The business has a fifty day moving average of $5.43 and a two-hundred day moving average of $5.88. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $7.91. The stock has a market cap of $280.55 million, a PE ratio of -3.18 and a beta of 1.33.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative net margin of 15,851.88% and a negative return on equity of 101.71%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.19 million. Analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.
Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of SLN. Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at $897,000. XTX Topco Ltd acquired a new position in Silence Therapeutics in the 4th quarter worth $71,000. Quadrature Capital Ltd bought a new position in Silence Therapeutics during the 4th quarter worth about $331,000. Opaleye Management Inc. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $480,000. Finally, Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after purchasing an additional 361,080 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.
About Silence Therapeutics (Get Free Report)
Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
Read More Five stocks we like better than Silence Therapeutics
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECoupang, Inc. (NYSE:CPNG) Given Consensus Rating of “Hold” by Brokerages
NEXT HEADLINE »Crane NXT, Co. (NYSE:CXT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Silence Therapeutics PLC Sponsored ADR (SLN - Free Report) shares rallied 19% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.
Silence Therapeutics’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments. SLN continues to advance its siRNA pipeline with multiple near-term catalysts. Its lead candidate, divesiran for polycythemia vera (PV), has seen accelerated timelines, with phase II SANRECO topline data expected in the third quarter 2026 due to faster enrollment. The company’s zerlasiran, targeting elevated lipoprotein(a), is Phase III–ready and could attract a development partner. In earlier stages, SLN365 for cholesterol and SLN098 for obesity are showing encouraging preclinical progress, underscoring the potential of its mRNAi GOLD platform, with multiple updates anticipated throughout 2026.
This company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of +45%. Revenues are expected to be $6 million, up 4185.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Silence Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SLN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Silence Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Guardian Pharmacy Services (GRDN - Free Report) , closed the last trading session 1.9% lower at $37.09. Over the past month, GRDN has returned 10.9%.
For Guardian Pharmacy, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.24. This represents a change of +14.3% from what the company reported a year ago. Guardian Pharmacy currently has a Zacks Rank of #1 (Strong Buy).
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2026, and provided an update on recent business achievements. “The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD™ platform, and we remain well positioned as we approach a significant company mile.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archiv.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be avail.
